The association between Akt activation and resistance to hormone therapy in metastatic breast cancer

Eriko Tokunaga, Akemi Kataoka, Yasue Kimura, Eiji Oki, Kojiro Mashino, Kojiro Nishida, Tadashi Koga, Masaru Morita, Yoshihiro Kakeji, Hideo Baba, Shinji Ohno, Yoshihiko Maehara

Research output: Contribution to journalArticle

92 Citations (Scopus)

Abstract

In this retrospective study, the relationship between Akt activation and the efficacy of endocrine therapy for metastatic breast cancer was investigated. Thirty-six metastatic breast cancer patients, treated with endocrine therapy, were evaluated for the activation of Akt by an immunohistochemical assessment of the expression of phosphorylated Akt at Ser 473 (pAkt). The relationship between the efficacy of endocrine therapy and Akt activation, HER2 status and hormone receptor expression was also investigated. Of these 36 cases, 12 cases (33.4%) were considered to show a positive pAkt expression. In the pAkt-positive patients, endocrine therapy demonstrated a worse efficacy than in pAkt-negative patients (P < 0.01). pAkt positivity was also associated with a poorer objective response (P < 0.05). The clinical benefit rate was lower in HER2 positive groups than in HER2 negative group (P < 0.05). In addition, the clinical benefit was the smallest in both the HER2 and pAkt-positive patients (P < 0.01). Regarding the endocrine agents, the clinical benefit of estrogen deprivation therapy with aromatase inhibitor or luteinising hormone-releasing hormone agosists was significantly lower in the pAkt-positive patients than that in the pAkt-negative ones (P < 0.05). In addition, there was a tendency for clinical benefit of selective estrogen receptor modulator to be smaller in the pAkt-positive patients (P = 0.09). These findings, therefore, suggest that Akt activation induces endocrine resistance in metastatic breast cancer, irrespective of the kind of endocrine agents that were administered. Our findings suggest that the activation of Akt in the downstream pathway of HER2 plays an important role in the resistance to endocrine therapy for breast cancer. Although our study was small in scope and retrospective in design, our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.

Original languageEnglish
Pages (from-to)629-635
Number of pages7
JournalEuropean Journal of Cancer
Volume42
Issue number5
DOIs
Publication statusPublished - Mar 1 2006

Fingerprint

Hormones
Breast Neoplasms
Therapeutics
Selective Estrogen Receptor Modulators
Aromatase Inhibitors
Gonadotropin-Releasing Hormone
Estrogens
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. / Tokunaga, Eriko; Kataoka, Akemi; Kimura, Yasue; Oki, Eiji; Mashino, Kojiro; Nishida, Kojiro; Koga, Tadashi; Morita, Masaru; Kakeji, Yoshihiro; Baba, Hideo; Ohno, Shinji; Maehara, Yoshihiko.

In: European Journal of Cancer, Vol. 42, No. 5, 01.03.2006, p. 629-635.

Research output: Contribution to journalArticle

Tokunaga, E, Kataoka, A, Kimura, Y, Oki, E, Mashino, K, Nishida, K, Koga, T, Morita, M, Kakeji, Y, Baba, H, Ohno, S & Maehara, Y 2006, 'The association between Akt activation and resistance to hormone therapy in metastatic breast cancer', European Journal of Cancer, vol. 42, no. 5, pp. 629-635. https://doi.org/10.1016/j.ejca.2005.11.025
Tokunaga, Eriko ; Kataoka, Akemi ; Kimura, Yasue ; Oki, Eiji ; Mashino, Kojiro ; Nishida, Kojiro ; Koga, Tadashi ; Morita, Masaru ; Kakeji, Yoshihiro ; Baba, Hideo ; Ohno, Shinji ; Maehara, Yoshihiko. / The association between Akt activation and resistance to hormone therapy in metastatic breast cancer. In: European Journal of Cancer. 2006 ; Vol. 42, No. 5. pp. 629-635.
@article{031ca7dc7d79408aba9b2795cafbdb17,
title = "The association between Akt activation and resistance to hormone therapy in metastatic breast cancer",
abstract = "In this retrospective study, the relationship between Akt activation and the efficacy of endocrine therapy for metastatic breast cancer was investigated. Thirty-six metastatic breast cancer patients, treated with endocrine therapy, were evaluated for the activation of Akt by an immunohistochemical assessment of the expression of phosphorylated Akt at Ser 473 (pAkt). The relationship between the efficacy of endocrine therapy and Akt activation, HER2 status and hormone receptor expression was also investigated. Of these 36 cases, 12 cases (33.4{\%}) were considered to show a positive pAkt expression. In the pAkt-positive patients, endocrine therapy demonstrated a worse efficacy than in pAkt-negative patients (P < 0.01). pAkt positivity was also associated with a poorer objective response (P < 0.05). The clinical benefit rate was lower in HER2 positive groups than in HER2 negative group (P < 0.05). In addition, the clinical benefit was the smallest in both the HER2 and pAkt-positive patients (P < 0.01). Regarding the endocrine agents, the clinical benefit of estrogen deprivation therapy with aromatase inhibitor or luteinising hormone-releasing hormone agosists was significantly lower in the pAkt-positive patients than that in the pAkt-negative ones (P < 0.05). In addition, there was a tendency for clinical benefit of selective estrogen receptor modulator to be smaller in the pAkt-positive patients (P = 0.09). These findings, therefore, suggest that Akt activation induces endocrine resistance in metastatic breast cancer, irrespective of the kind of endocrine agents that were administered. Our findings suggest that the activation of Akt in the downstream pathway of HER2 plays an important role in the resistance to endocrine therapy for breast cancer. Although our study was small in scope and retrospective in design, our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.",
author = "Eriko Tokunaga and Akemi Kataoka and Yasue Kimura and Eiji Oki and Kojiro Mashino and Kojiro Nishida and Tadashi Koga and Masaru Morita and Yoshihiro Kakeji and Hideo Baba and Shinji Ohno and Yoshihiko Maehara",
year = "2006",
month = "3",
day = "1",
doi = "10.1016/j.ejca.2005.11.025",
language = "English",
volume = "42",
pages = "629--635",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "5",

}

TY - JOUR

T1 - The association between Akt activation and resistance to hormone therapy in metastatic breast cancer

AU - Tokunaga, Eriko

AU - Kataoka, Akemi

AU - Kimura, Yasue

AU - Oki, Eiji

AU - Mashino, Kojiro

AU - Nishida, Kojiro

AU - Koga, Tadashi

AU - Morita, Masaru

AU - Kakeji, Yoshihiro

AU - Baba, Hideo

AU - Ohno, Shinji

AU - Maehara, Yoshihiko

PY - 2006/3/1

Y1 - 2006/3/1

N2 - In this retrospective study, the relationship between Akt activation and the efficacy of endocrine therapy for metastatic breast cancer was investigated. Thirty-six metastatic breast cancer patients, treated with endocrine therapy, were evaluated for the activation of Akt by an immunohistochemical assessment of the expression of phosphorylated Akt at Ser 473 (pAkt). The relationship between the efficacy of endocrine therapy and Akt activation, HER2 status and hormone receptor expression was also investigated. Of these 36 cases, 12 cases (33.4%) were considered to show a positive pAkt expression. In the pAkt-positive patients, endocrine therapy demonstrated a worse efficacy than in pAkt-negative patients (P < 0.01). pAkt positivity was also associated with a poorer objective response (P < 0.05). The clinical benefit rate was lower in HER2 positive groups than in HER2 negative group (P < 0.05). In addition, the clinical benefit was the smallest in both the HER2 and pAkt-positive patients (P < 0.01). Regarding the endocrine agents, the clinical benefit of estrogen deprivation therapy with aromatase inhibitor or luteinising hormone-releasing hormone agosists was significantly lower in the pAkt-positive patients than that in the pAkt-negative ones (P < 0.05). In addition, there was a tendency for clinical benefit of selective estrogen receptor modulator to be smaller in the pAkt-positive patients (P = 0.09). These findings, therefore, suggest that Akt activation induces endocrine resistance in metastatic breast cancer, irrespective of the kind of endocrine agents that were administered. Our findings suggest that the activation of Akt in the downstream pathway of HER2 plays an important role in the resistance to endocrine therapy for breast cancer. Although our study was small in scope and retrospective in design, our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.

AB - In this retrospective study, the relationship between Akt activation and the efficacy of endocrine therapy for metastatic breast cancer was investigated. Thirty-six metastatic breast cancer patients, treated with endocrine therapy, were evaluated for the activation of Akt by an immunohistochemical assessment of the expression of phosphorylated Akt at Ser 473 (pAkt). The relationship between the efficacy of endocrine therapy and Akt activation, HER2 status and hormone receptor expression was also investigated. Of these 36 cases, 12 cases (33.4%) were considered to show a positive pAkt expression. In the pAkt-positive patients, endocrine therapy demonstrated a worse efficacy than in pAkt-negative patients (P < 0.01). pAkt positivity was also associated with a poorer objective response (P < 0.05). The clinical benefit rate was lower in HER2 positive groups than in HER2 negative group (P < 0.05). In addition, the clinical benefit was the smallest in both the HER2 and pAkt-positive patients (P < 0.01). Regarding the endocrine agents, the clinical benefit of estrogen deprivation therapy with aromatase inhibitor or luteinising hormone-releasing hormone agosists was significantly lower in the pAkt-positive patients than that in the pAkt-negative ones (P < 0.05). In addition, there was a tendency for clinical benefit of selective estrogen receptor modulator to be smaller in the pAkt-positive patients (P = 0.09). These findings, therefore, suggest that Akt activation induces endocrine resistance in metastatic breast cancer, irrespective of the kind of endocrine agents that were administered. Our findings suggest that the activation of Akt in the downstream pathway of HER2 plays an important role in the resistance to endocrine therapy for breast cancer. Although our study was small in scope and retrospective in design, our findings suggest that pAkt may be a useful predictor of resistance to endocrine therapy for breast cancer, while also suggesting that the inhibition of Akt may increase the efficacy of endocrine therapy.

UR - http://www.scopus.com/inward/record.url?scp=33644755478&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644755478&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2005.11.025

DO - 10.1016/j.ejca.2005.11.025

M3 - Article

C2 - 16464571

AN - SCOPUS:33644755478

VL - 42

SP - 629

EP - 635

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0959-8049

IS - 5

ER -